A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Inclusion Criteria: * Body mass index (BMI) is \>= 18.0 to \= 35 kg. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). Exclusion Criteria: * Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements, on a regular basis. * Participant uses any medications, vitamins and/or herbal supplements within the 14-day period prior to study treatment administration. * Participant has received any treatment by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study treatment administration. * Participant has prior exposure to a Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) agent.